First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal Cell Carcinoma.

MLA

Powles, Thomas, et al. “First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal Cell Carcinoma.” Journal of Oncology Navigation & Survivorship, vol. 10, no. 8, Aug. 2019, pp. 317–18. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=137759380&authtype=sso&custid=ns315887.

APA

Powles, T., Pal, S. K., & Wood, L. (2019). First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal Cell Carcinoma. Journal of Oncology Navigation & Survivorship, 10(8), 317–318.

Chicago

Powles, Thomas, Sumanta K. Pal, and Lori Wood. 2019. “First-Line Pembrolizumab plus Axitinib Combination Boosts Survival in Metastatic Renal Cell Carcinoma.” Journal of Oncology Navigation & Survivorship 10 (8): 317–18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=137759380&authtype=sso&custid=ns315887.